Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Therapeutic antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Biochemical Assay Reagents (2) CD19 (1) CD28 (1) Claudin (1) Discoidin Domain Receptor (1) Endogenous Metabolite (1) Isotope-Labeled Compounds (2) Radionuclide-Drug Conjugates (RDCs) (1) SARS-CoV (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9975

Theralizumab TGN1412; TAB08	CD28	Inflammation/Immunology
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .

HY-134669

CypK N-Cyclopropene-L-Lysine	Amino Acid Derivatives	Cancer
CypK (N-Cyclopropene-L-Lysine), a cyclopropene derivative of lysine, is efficiently incorporated into antibodies through genetic-code expansion. CypK is a minimal bioorthogonal handle for the creation of stable therapeutic protein conjugates .

HY-NP194

Cyclosporin A-BSA	Biochemical Assay Reagents	Inflammation/Immunology
Cyclosporin A-BSA is a conjugate of Cyclosporin A (HY-B0579) and BSA, primarily used as an immunogen to generate antibodies against Cyclosporin A for therapeutic drug monitoring and research assays .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-W440902

DSPE-PEG3400-IA	Biochemical Assay Reagents	Others
DSPE-PEG3400-IA is an iodoacetyll PEG lipid. The polymer can form lipid bilayer or micelles spontaneoulsy in water. The lipophilic tails can be used to encapsulate hydrophobic therapeutic agents while the hydrophilic head can be used to encapuslate hydrophilic drugs/nutrient, such as antibody, mRNA/DNA. The iodoacetyl group is reactive with thiol to produce a thioether linkage.

HY-P5201S

VTSEGAGLQLQK-13C6,15N2	Isotope-Labeled Compounds	Others
VTSEGAGLQLQK-13C6,15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .

HY-P5201S1

VTSEGAGLQLQK-13C6,15N2 TFA	Isotope-Labeled Compounds	Others
VTSEGAGLQLQK-13C6,15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .

HY-P991895

PLG-101	Transmembrane Glycoprotein	Cardiovascular Disease
PLG-101 is a human anti-CD8 antibody. PLG-101 can be used in research on acute myocardial infarction .

HY-P992508

SPX-101 SX001	Claudin	Cancer
SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.

HY-W854443

L-Fucose 6-Deoxy-L-galactopyranose	Endogenous Metabolite	Inflammation/Immunology Cancer
L-Fucose (6-Deoxy-L-galactopyranose) is an orally active dietary sugar. L-Fucose is one of the key metabolites involved in the interaction between humans and the intestinal microbiota. L-Fucose binds to proteins as a post-translational modification through the fucosylation process, thereby regulating the behavior and function of proteins. L-Fucose has shown the ability to inhibit tumor growth and increase the infiltration of immune cells within tumors. L-Fucose can be used in cancer and anti-tumor immune research .

HY-P992066

Anti-Mouse DDR2 Antibody (DAB0065)	Discoidin Domain Receptor	Inflammation/Immunology
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

Cat. No.	Product Name

HY-L177

Antibody Inhibitor Library	1,777 compounds
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,777 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Antibody Inhibitor Library

1,777 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 1,777 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Cat. No.	Product Name	Type

HY-NP194

Cyclosporin A-BSA	Biochemical Assay Reagents
Cyclosporin A-BSA is a conjugate of Cyclosporin A (HY-B0579) and BSA, primarily used as an immunogen to generate antibodies against Cyclosporin A for therapeutic drug monitoring and research assays .

HY-W440902

DSPE-PEG3400-IA	Biochemical Assay Reagents
DSPE-PEG3400-IA is an iodoacetyll PEG lipid. The polymer can form lipid bilayer or micelles spontaneoulsy in water. The lipophilic tails can be used to encapsulate hydrophobic therapeutic agents while the hydrophilic head can be used to encapuslate hydrophilic drugs/nutrient, such as antibody, mRNA/DNA. The iodoacetyl group is reactive with thiol to produce a thioether linkage.

Cat. No.	Product Name	Target	Research Area

HY-P5201S1

VTSEGAGLQLQK-13C6,15N2 TFA	Isotope-Labeled Compounds	Others
VTSEGAGLQLQK-13C6,15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9975

Theralizumab TGN1412; TAB08	CD28	Inflammation/Immunology
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-P991895

PLG-101	Transmembrane Glycoprotein	Cardiovascular Disease
PLG-101 is a human anti-CD8 antibody. PLG-101 can be used in research on acute myocardial infarction .

HY-P992508

SPX-101 SX001	Claudin	Cancer
SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.

HY-P992066

Anti-Mouse DDR2 Antibody (DAB0065)	Discoidin Domain Receptor	Inflammation/Immunology
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

Cat. No.	Product Name	Chemical Structure

HY-P5201S

VTSEGAGLQLQK-13C6,15N2
VTSEGAGLQLQK-13C6,15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .

HY-P5201S1

VTSEGAGLQLQK-13C6,15N2 TFA
VTSEGAGLQLQK-13C6,15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.